Preclinical News and Research

RSS
Most high-risk CV devices approved without clinical data

Most high-risk CV devices approved without clinical data

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

Study: CIEDs used by physicians today were approved as supplements to premarket approved models

Study: CIEDs used by physicians today were approved as supplements to premarket approved models

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Researchers identify molecular mechanism by which cocaine alters brain's reward circuits, causes addiction

Researchers identify molecular mechanism by which cocaine alters brain's reward circuits, causes addiction

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

Research uncovers new mechanism in brain cells that may help keep deadly neurological diseases in check

Research uncovers new mechanism in brain cells that may help keep deadly neurological diseases in check

Research findings may offer new way to treat prion diseases

Research findings may offer new way to treat prion diseases

FDA-regulated study investigates use of child's stem cells for acquired sensorineural hearing loss

FDA-regulated study investigates use of child's stem cells for acquired sensorineural hearing loss

New discovery has potential to transform heart attack treatments

New discovery has potential to transform heart attack treatments

MRI method to map creatine in heart may help detect disorders earlier than traditional methods

MRI method to map creatine in heart may help detect disorders earlier than traditional methods

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Immune tolerance to grafts of muscle, bone and skin could free recipients from lifelong immunosuppression

Immune tolerance to grafts of muscle, bone and skin could free recipients from lifelong immunosuppression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.